Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-12T22:28:19.276Z Has data issue: false hasContentIssue false
  • English
  • Français

The fate of moclobemide

Published online by Cambridge University Press:  16 April 2020

K. Martiny
K. Martiny*
Affiliation:
Psychiatric Research Unit, Frederiksborg General Hospital, Hillerød, Denmark

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The introduction of the reversible monoamine oxidase-A inhibitor moclobemid was a promising development of the MAO inhibitor principle in the treatment af major depression. The irreversible MAO inhibitors has severe interactions with a broad range of drugs and patients needs to be very alert regarding specific dietary components such as redwine, cheese and so on. In spite of investigations showing promising results and a very beneficial side effect profile, the drug is currently not much used. This presentation reviews the principal studies included the DUAG study on moclobemide and tries to explain the fate of moclobemid.

Type
S31. Symposium: 25 Years of Experiences with Various Types of Antidepressants: The Danish University Antidepressant Group
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S50
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.